Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Will Califf’s Attention To Foods Come At Expense Of US FDA’s Drugs Program?

Executive Summary

FDA Commissioner Robert Califf says the medical product programs have received a lot of attention and now it’s the food program’s turn.

You may also be interested in...



Pharma Remains In US FDA Back Seat As Food, Tobacco Priorities Take Center Stage

FDA Deputy Commissioner for Policy, Legislation and International Affairs Kimberlee Trzeciak has non-medical product work at top of her agenda, highlighting shift in attention that has been a mainstay of FDA commissioner Robert Califf's tenure.

Pharma Continues To Sit In Back Seat As Tobacco, Food Priorities Take Center Stage At FDA

New FDA Deputy Commissioner for Policy, Legislation and International Affairs Kimberlee Trzeciak has non-medical product work on the top of her agenda, highlighting the shift in attention that has been a mainstay of FDA commissioner Robert Califf's tenure.

Batch Testing Of All Imported Drugs Floated At House Appropriations Hearing

While food oversight dominated lawmakers' attention, Republicans and Democrats were united on need to onshore more drug manufacturing to the US as FDA Commissioner Robert Califf testified about the agency’s fiscal year 2024 budget request.

Related Content

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS147736

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel